Word

AMNYPO

Status

Dead

Status Code

602

Status Date

Friday, July 7, 2023

Serial Number

97484150

Mark Type

3000

Filing Date

Thursday, June 30, 2022

Abandoned Date

Friday, June 23, 2023

Trademark Owner History

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Classifications

5 Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical purposes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of human illnesses, namely, anti-tumor treatment; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical products for the prevention and treatment of cancer; Aloe vera preparations for pharmaceutical purposes; Bismuth preparations for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and tumor; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations, namely, elixirs for the treatment of anti-tumor treatment and cancer; Potassium preparations for pharmaceutical purposes; Sunburn preparations for pharmaceutical purposes

The mark consists of the stylized wording "AMNYPO" with a design showing gene mutation.
The wording AMNYPO has no meaning in a foreign language.

Trademark Events

Jul 10, 2023

Abandonment Notice E-Mailed - Failure To Respond

Jul 7, 2023

Abandonment Notice Mailed - Failure To Respond

Jul 7, 2023

Abandonment - Failure To Respond Or Late Response

Mar 22, 2023

Notification Of Non-Final Action E-Mailed

Mar 22, 2023

Non-Final Action E-Mailed

Mar 22, 2023

Non-Final Action Written

Mar 22, 2023

Assigned To Examiner

Jul 21, 2022

Notice Of Design Search Code E-Mailed

Jul 20, 2022

New Application Office Supplied Data Entered

Jul 4, 2022

New Application Entered